Elezanumab (ABT-555)

Elezanumab (ABT-555) is a monoclonal antibody RGMa inhibitor being investigated to treat spinal cord injuries, multiple sclerosis and acute ischemic stroke.

Type of Molecule

Biologic

Target

RGMa

Product Type

New Indication
Potential Indication Region Phase (1, 2, 3, Submitted)
Multiple Sclerosis n/a
Phase 2
Acute Ischemic Stroke n/a
Phase 2
Spinal Cord Injury n/a
Phase 2